Overall market sentiment has been down on Otonomy Inc (OTIC) stock lately. OTIC receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With OTIC Stock Today?
Otonomy Inc (OTIC) stock is trading at $3.00 as of 10:55 AM on Wednesday, Feb 24, a gain of $0.11, or 3.99% from the previous closing price of $2.88. The stock has traded between $2.78 and $3.03 so far today. Volume today is less active than usual. So far 788,915 shares have traded compared to average volume of 1,447,302 shares.
To see the top 5 stocks in the Biotechnology industry click here.
More About Otonomy Inc
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
Click Here to get the full Stock Score Report on Otonomy Inc (OTIC) Stock.
